Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
EfGPdPKkLN7XbBbk
Listen
